CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 12.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 15,700 shares of the company’s stock after acquiring an additional 1,700 shares during the period. Handelsbanken Fonder AB’s holdings in CRISPR Therapeutics were worth $983,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth $32,000. Bourgeon Capital Management LLC increased its stake in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the period. CWM LLC lifted its holdings in CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after buying an additional 260 shares in the last quarter. TFC Financial Management Inc. boosted its position in CRISPR Therapeutics by 3,400.0% in the 4th quarter. TFC Financial Management Inc. now owns 700 shares of the company’s stock valued at $44,000 after buying an additional 680 shares during the last quarter. Finally, Tradewinds Capital Management LLC grew its stake in shares of CRISPR Therapeutics by 545.5% during the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after acquiring an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of analyst reports. Chardan Capital increased their price target on CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Wells Fargo & Company raised their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. Mizuho lifted their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Royal Bank of Canada increased their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research note on Thursday, February 22nd. Finally, Barclays boosted their target price on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Trading Up 0.3 %

NASDAQ:CRSP opened at $53.91 on Monday. The firm has a market capitalization of $4.58 billion, a PE ratio of -27.50 and a beta of 1.76. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The stock has a 50 day moving average of $70.57 and a 200-day moving average of $64.08.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. CRISPR Therapeutics’s quarterly revenue was up 3253.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.41) earnings per share. As a group, analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. Over the last quarter, insiders sold 83,992 shares of company stock worth $6,132,335. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.